文献速递白血病

细胞极性决定因子CDC42控制分裂对称性以阻断白血病细胞分化

The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation.
PubMed 文献 · Blood · 2017-08-04

研究发现造血干/祖细胞转化为急性髓系白血病(AML)时CDC42表达与活性升高,小鼠模型中敲除Cdc42可阻止MLL-AF9诱导的AML发生;在鼠源和人源MLL-AF9细胞中敲除CDC42降低克隆性白血病起始细胞存活并诱导其分化,诱导性抑制CDC42可阻断人原代AML细胞在小鼠异种移植模型中的白血病进展。

要点

  • AML转化伴随白血病细胞CDC42表达与活性升高。
  • 敲除Cdc42可阻止MLL-AF9诱导的小鼠AML发生。
  • 抑制CDC42降低白血病起始细胞存活并诱导分化、阻断移植模型白血病进展。

核心结论

  • CDC42缺失抑制AML细胞极性与分裂不对称性,CDC42是改变白血病起始细胞命运以实现分化治疗的可用靶点。

研究设计与样本

  • 研究使用小鼠AML模型、鼠源和人源MLL-AF9(MA9)细胞及人原代AML细胞异种移植模型进行实验。

主要发现

  • HSC/P向AML转化与白血病细胞CDC42表达和活性升高相关。
  • 小鼠AML模型中Cdc42缺失阻止MLL-AF9诱导的AML发生。
  • 鼠源和人源MA9细胞中CDC42基因敲除降低克隆性白血病起始细胞存活并诱导其分化。
  • MA9白血病细胞在Cdc42-GTP活性升高背景下维持细胞极性,类似非恶性年轻HSC/P。
  • Cdc42缺失使AML细胞去极化,与产生可自我更新子细胞的对称和不对称分裂频率下降相关。

临床怎么用

  • 作者认为CDC42是改变白血病起始细胞命运以实现分化治疗的可用靶点。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

As a central regulator of cell polarity, the activity of CDC42 GTPase is tightly controlled in maintaining normal hematopoietic stem and progenitor cell (HSC/P) functions. We found that transformation of HSC/P to acute myeloid leukemia (AML) is associated with increased CDC42 expression and activity in leukemia cells. In a mouse model of AML, the loss of Cdc42 abrogates MLL-AF9-induced AML development. Furthermore, genetic ablation of CDC42 in both murine and human MLL-AF9 (MA9) cells decreased survival and induced differentiation of the clonogenic leukemia-initiating cells. We show that MLL-AF9 leukemia cells maintain cell polarity in the context of elevated Cdc42-guanosine triphosphate activity, similar to nonmalignant, young HSC/Ps. The loss of Cdc42 resulted in a shift to depolarized AML cells that is associated with a decrease in the frequency of symmetric and asymmetric cell divisions producing daughter cells capable of self-renewal. Importantly, we demonstrate that inducible CDC42 suppression in primary human AML cells blocks leukemia progression in a xenograft model. Thus, CDC42 loss suppresses AML cell polarity and division asymmetry, and CDC42 constitutes a useful target to alter leukemia-initiating cell fate for differentiation therapy.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Mizukawa B, O'Brien E, Moreira DC, et al. The cell polarity determinant CDC42 controls division symmetry to block leukemia cell differentiation. Blood. 2017. PMID: 28778865. doi:10.1182/blood-2016-12-758458

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。